Enabling Anyone to Translate Clinically Relevant Ideas to Therapies

How do we inspire new ideas that could lead to potential treatments for rare or neglected diseases, and allow for serendipity that could help to catalyze them? How many potentially good ideas are lost because they are never tested? What if those ideas could have lead to new therapeutic approaches an...

Full description

Saved in:
Bibliographic Details
Published in:Pharmaceutical research 2017, Vol.34 (1), p.1-6
Main Authors: Ekins, Sean, Diaz, Natalie, Chung, Julia, Mathews, Paul, McMurtray, Aaron
Format: Article
Language:English
Subjects:
Animals
Biochemistry
Biomedical and Life Sciences
Biomedical Engineering and Bioengineering
Biomedicine
Cooperative Behavior
Drug Discovery
Drug Industry - methods
Drug therapy
Humans
Laboratories
Medical Law
Neglected Diseases - drug therapy
Neglected Diseases - therapy
Perspective
Pharmacology
Pharmacology/Toxicology
Pharmacy
Therapeutics - methods
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:How do we inspire new ideas that could lead to potential treatments for rare or neglected diseases, and allow for serendipity that could help to catalyze them? How many potentially good ideas are lost because they are never tested? What if those ideas could have lead to new therapeutic approaches and major healthcare advances? If a clinician or anyone for that matter, has a new idea they want to test to develop a molecule or therapeutic that they could translate to the clinic, how would they do it without a laboratory or funding? These are not idle theoretical questions but addressing them could have potentially huge economic implications for nations. If we fail to capture the diversity of ideas and test them we may also lose out on the next blockbuster treatments. Many of those involved in the process of ideation may be discouraged and simply not know where to go. We try to address these questions and describe how there are options to raising funding, how even small scale investments can foster preclinical or clinical translation, and how there are several approaches to outsourcing the experiments, whether to collaborators or commercial enterprises. While these are not new or far from complete solutions, they are first steps that can be taken by virtually anyone while we work on other solutions to build a more concrete structure for the “idea—hypothesis testing—proof of concept—translation—breakthrough pathway”.
ISSN:0724-8741
1573-904X
DOI:10.1007/s11095-016-2039-5